|
|||||
|
|
Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-α antagonist therapy: safe re-initiation of TNF-α blockers after appropriate anti-tuberculous treatment |
|
| Authors: | B. Denis A. Lefort R. M. Flipo F. Tubach M. Lemann P. Ravaud D. Salmon X. Mariette O. Lortholary |
| Affiliation: | UniversitéParis V, Hôpital Necker-Enfants Malades, Service des Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, Paris;, UniversitéParis VII, Service de Médecine Interne, Hôpital Beaujon, Clichy;, Service de Rhumatologie, CHU, Lille;, UniversitéParis 7, Groupe Hospitalier Bichat-Claude Bernard, Département d'Epidémiologie, Biostatistique et Recherche Clinique, Institut National de la Santéet de la Recherche Médicale, U738;, UniversitéParis 7, Hôpital Saint Louis, Service de Gastro-Entérologie;, UniversitéParis V, Hôpital Cochin, Service de Médecine Interne, Paris;and UniversitéParis XI, Hôpital du Kremlin-Bicêtre, Service de Rhumatologie, Le Kremlin-Bicêtre, France |
| Abstract: | This study investigated the long-term outcome of patients with tuberculosis (TB) as a complication of tumour necrosis factor (TNF)-α blocker therapy. All TB cases ( n = 21) complicating TNF-α blocker therapy from French university hospitals were collated between January 2000 and September 2002. Outcome was assessed via a postal questionnaire during September 2005. The mortality rate after 4 years was 4.8%, and one patient had relapsed and six (29%) patients had recommenced TNF-α antagonist treatment, after appropriate anti-TB therapy, without reactivation. These data support the concept that TNF-α antagonists can be restarted in TB patients provided that adequate anti-TB treatment has been completed. |
| Keywords: | Antagonist treatment mortality rate Mycobacterium tuberculosis tuberculosis tumour necrosis factor (TNF)-α |